Caroline Redeker

Background

About Caroline Redeker

Clinical Research Innovator, Leader and Mentor with over 30 years of experience in creating new solutions and adding value to clinical development programs. Current member of Healthcare Businesswomen's Association (HBA), and Decentralized Trials Research Alliance (DTRA). Caroline is an award winner of the PharmaVoice 100 and HBA Luminary awards. Caroline is passionate about developing meaningful and authentic relationships with all stakeholders in the clinical development process, including the patients. Being closer to the patients and their needs is what drove Caroline to her current role at StuffThatWorks, where she will be commercializing the first patient-driven intelligence platform that provides meaningful insights to pharma for trial optimization, drug repurposing, and commercialization strategies. More importantly, it provides a community for patients to share experiences and learn from others. Previously, Caroline has led the growth of 2 CROs over 25 years. She was primarily responsible for developing strategic and commercial business plans and teams, including marketing, proposals and sales teams. Leader and Corporate Officer for one of the first large, independent clinical research sites in 1990s. Key leader in helping grow three companies into merger/ acquisition stages and oversaw multiple merger integrations within SMO and CRO companies. Expertise in strategic consulting, clinical development planning, global project feasibility, site start-up and management, patient recruitment, innovative technologies, and a full suite of CRO services. Key experiences in study rescue and transition programs, with processes and strategies for both full CRO study management transition as well as functional service provider (FSP) programs. Responsible for developing and managing key strategic relationships across the globe. Current Company:StuffThatWorks is the first patient intelligence platform that transforms real-world patient experiences into actionable intelligence and provides access directly to the patients. Platform datasets include over 3 million patients across 1,250 conditions, with 1.3 billion data points. Using patient-reported data and a patient-derived foundational AI model, STW enhances trial optimization, drug repurposing, and commercial strategies.